Pancreatic Cancer Research

ResearcherUniversity of CincinnatiActive in the last 2 years

Jordan R. Kharofa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5091-6090; OpenAlex author ID A5031132761. Sources: OpenAlex.

Their work

Papers
14 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 5 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. Assessing Response and Outcomes to Modern Multiagent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-19990-7↗
  2. ASO Visual Abstract: Assessing Response and Outcomes to Modern Multi-Agent Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20039-y↗
  3. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  4. Indications for Radiation in Pancreatic Adenocarcinoma: A Review. Last author DOI 10.1016/j.suc.2024.05.003↗
  5. The Role of Dose Escalation in Pancreatic Cancer: Go Big or Go Home? First author DOI 10.1016/j.ijrobp.2022.09.050↗
  6. Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More. First author DOI 10.1016/j.ijrobp.2021.08.024↗
  7. Radiation therapy in borderline resectable pancreatic cancer: A review. Co-author DOI 10.1016/j.surg.2021.12.013↗
  8. Systemic Therapy for Resected Pancreatic Adenocarcinoma: How Much is Enough? Co-author DOI 10.1245/s10434-022-11363-0↗
  9. Is There a Benefit to Adjuvant Chemotherapy in Resected, Early Stage Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.1245/s10434-022-11580-7↗
  10. Relationship of dose to vascular target volumes and local failure in pancreatic cancer patients undergoing neoadjuvant chemoradiation. Last author DOI 10.3389/fonc.2022.906484↗
  11. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment. Co-author DOI 10.1016/j.jss.2020.09.009↗
  12. Comparison of Radiation Treatment Volumes for Borderline Resectable Pancreatic Cancer in Contemporary Clinical Trials. First author DOI 10.1097/coc.0000000000000726↗
  13. Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Can… Last author DOI 10.1097/mpa.0000000000001602↗
  14. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.radonc.2014.09.010↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olugbenga Olanrele Olowokure · 7 shared papers, 2020–2026 · strength 1.21
  2. Sameer H. Patel · 7 shared papers, 2020–2026 · strength 1.21
  3. Davendra P. S. Sohal · 5 shared papers, 2022–2026 · strength 0.97
  4. Gregory C. Wilson · 5 shared papers, 2022–2026 · strength 0.97
  5. Syed Ameen Ahmad · 5 shared papers, 2020–2022 · strength 0.69
  6. Bailey A. Nelson · 2 shared papers, 2022–2024 · strength 0.55
  7. Ryan P. Johnson · 2 shared papers, 2026 · strength 0.53
  8. Syed A. Ahmad · 2 shared papers, 2026 · strength 0.53
  9. Paul H. McClelland · 2 shared papers, 2026 · strength 0.53
  10. Kevin M. Turner · 3 shared papers, 2022 · strength 0.44
  11. Joshua E. Meyer · 1 shared paper, 2023 · strength 0.39
  12. Samuel J. Keltner · 1 shared paper, 2024 · strength 0.36
  13. Michelle F. Barrord · 2 shared papers, 2020–2022 · strength 0.29
  14. Nina Niu Sanford · 1 shared paper, 2022 · strength 0.26
  15. Michael David Chuong · 1 shared paper, 2022 · strength 0.26
  16. Douglas B. Evans · 2 shared papers, 2014–2025 · strength 0.24
  17. Susan Tsai · 2 shared papers, 2014–2025 · strength 0.24
  18. Kathleen K. Christians · 2 shared papers, 2014–2025 · strength 0.24
  19. Trevor S. Bluemel · 1 shared paper, 2020 · strength 0.24
  20. William Adrian Hall · 1 shared paper, 2025 · strength 0.20
  21. Sara Beltrán Ponce · 1 shared paper, 2025 · strength 0.20
  22. Callisia Nathelee Clarke · 1 shared paper, 2025 · strength 0.20
  23. Ben George · 1 shared paper, 2025 · strength 0.20
  24. E.S. Paulson · 1 shared paper, 2025 · strength 0.20
  25. Mohammed Aldakkak · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.